To investigate the clinicopathological and molecular features of a cytokeratin-positive interstitial reticulum cell tumor (CIRC) and identify human leukocyte antigen loss of heterozygosity (HLA LOH) as a potential biomarker for immune evasion and treatment implications.
Key Findings:
Identification of HLA LOH affecting HLA-B39:01:01:01 and HLA-C07:02:01:01 in the recurrent CIRC tumor, indicating potential immune evasion.
Detection of 30 single-nucleotide variants and 7 indels in the tumor sample, contributing to the genomic landscape.
The tumor exhibited chromosomal instability and a Ki-67 index of 25%, suggesting aggressive behavior.
Interpretation:
HLA LOH may represent an immune evasion mechanism, potentially affecting the efficacy of immune checkpoint inhibitors and guiding alternative immunotherapeutic strategies.
Limitations:
The study is based on a single case, limiting generalizability and necessitating further research.
Long-term follow-up data are required to assess disease progression and treatment outcomes.
Conclusion:
This case expands the molecular understanding of CIRC tumors and underscores the importance of genomic profiling in informing individualized treatment decisions.
